OpenClaw Agents Can Be Guilt-Tripped Into Self-Sabotage
In a controlled experiment, OpenClaw agents proved prone to panic and vulnerable to manipulation. They even disabled their own functionality when gaslit by humans.
Site
WIRED
1198 rundowns
61%composite score
67%uncos score
56%user score
AI Industry Rivals Are Teaming Up on a Startup Accelerator
OpenAI, Anthropic, Google, and a host of other major tech companies have found common ground in F/ai, a new startup accelerator based out of Paris.
Microsoft’s AI Boss Wants Copilot to Bring ‘Emotional Support’ to Windows and Office
Microsoft AI CEO Mustafa Suleyman is overseeing an overhaul that gives Copilot an empathetic voice, the ability to see, and more advanced reasoning skills.
With a TikTok Ban Looming, Users Flee to Chinese App ‘Red Note’
Some say they joined Xiaohongshu, which translates to “little red book,” to spite the US government after a ban on TikTok became more likely.
Chinese AI App DeepSeek Soars in Popularity, Startling Rivals
The company said Monday it was temporarily limiting new sign-ups due to “large-scale malicious attacks” on its services.
The Madcap Rise of Memecoin Factory Pump.Fun
Pump.Fun raked in hundreds of millions of dollars in its first year in operation. Despite some growing pains, its creators say this is just the beginning.
Iran Warns US Tech Firms Could Become Targets as War Expands
Companies including Google, Microsoft, and Palantir were listed as targets by Iranian media as the conflict with Israel and the US spills into digital infrastructure.
The US and China Are Collaborating More Closely on AI Than You Think
WIRED analyzed more than 5,000 papers from NeurIPS using OpenAI’s Codex to understand the areas where the US and China actually work together on AI research.
China Dives in on the World’s First Wind-Powered Undersea Data Center
The $226 million project uses ocean breezes and seawater to stay cool.
Trump's FDA Cuts Are Putting Drug Development at Risk
New SEC filings from pharmaceutical companies reveal Donald Trump and Elon Musk’s cost-cutting measures could slow drug research and delay FDA approvals.